Nucleus Network begins dosing for third COVID-19 vaccine trial in Australia

Australia’s largest Phase 1 Clinical trials specialist, Nucleus Network, has commenced dosing the first human participants for the Phase 1/2 trial COVID-19 Vaccine trial in collaboration with the vaccine’s developer Serum Institute of India Pvt. Ltd in partnership with the local sponsor, Accelagen Pty Ltd.
30 healthy participants, aged 18 to 59 years of age, have been screened to take part in Phase 1 of the trial under the guidance of Nucleus Network’s leading expert in infectious disease Principal Investigator Assoc. Professor Paul Griffin. Phase 2 of the trial will include 250 participants and is expected to commence in October.
Nucleus Network is now administering three of approximately 36 in-human COVID-19 Phase 1 and 2 vaccine trials globally, with The University of Queensland and Novavax also selecting Nucleus Network to conduct their trials. This makes Nucleus one of the only Phase 1 clinical trials specialist entrusted to undertake multiple COVID-19 vaccine trials anywhere in the world.

https://www.nucleusnetwork.com/news/nucleus-network-begins-dosing-for-third-covid-19-vaccine-trial/

If you want to read this article in Japanese, please see the following link:
https://www.j-abc.com/jp-blog/nucleus-networkcovid-193.html?lang=ja 
​